Back To: Home : Featured Technology : Gene and Cell Therapies

CLICK HERE FOR WHAT'S NEW IN:
 

Agilent makes $21M investment in Gen9
June 2013
SHARING OPTIONS:

CAMBRIDGE, Mass.Gen9 Inc. and Agilent Technologies Inc. have closed a $21 million strategic investment from Agilent in Gen9, which plans to use the funding to investment in product development and the expansion of commercial infrastructure for its synthetic biology business. The investment has gained Agilent an equity stake in the company as well as a spot on Gen9's board of directors. In conjunction with this development, Gen9 will incorporate Agilent's Oligonucleotide Library Synthesis technology into its manufacturing process to support the large-scale creation of pathway constructs and DNA libraries.  
 
"Agilent's investment is a powerful validation of our proprietary BioFab platform, and we look forward to working closely with them to further innovate around our manufacturing capabilities and build Gen9 into the leading high- throughput supplier to the synthetic biology marketplace," Kevin Munnelly, president and CEO of Gen9, commented in a statement.

Back

PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.